Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:80829 |
Name | low grade glioma |
Definition | A cell type benign neoplasm that has_material_basis_in glial cells (astrocytes, oligodendrocytes or ependymocytes). |
Source | DiseaseOntology.org |
Alt Ids | DOID:0060101 |
Path | disease disease of cellular proliferation benign neoplasm cell type benign neoplasm low grade glioma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V600X | Dabrafenib | low grade glioma | predicted - sensitive | detail... |
IDH1 R132H | Ivosidenib | low grade glioma | predicted - sensitive | detail... |
IDH1 R132X | Ivosidenib | low grade glioma | predicted - sensitive | detail... |
NTRK1 fusion | Larotrectinib | low grade glioma | sensitive | detail... |
NTRK2 fusion | Larotrectinib | low grade glioma | sensitive | detail... |
NTRK2 fusion | Entrectinib | low grade glioma | sensitive | detail... |
NTRK1 fusion | Entrectinib | low grade glioma | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | low grade glioma | sensitive | detail... |
BRAF V600E | Cobimetinib + Vemurafenib | low grade glioma | sensitive | detail... |
BRAF fusion | Ulixertinib | low grade glioma | predicted - sensitive | detail... |
BRAF V600X | Trametinib | low grade glioma | predicted - sensitive | detail... |
BRAF V600X | Dabrafenib + Trametinib | low grade glioma | predicted - sensitive | detail... |
FGFR1 act mut | Erdafitinib | low grade glioma | predicted - sensitive | detail... |
BRAF fusion | Tovorafenib | low grade glioma | predicted - sensitive | detail... |
BRAF V600E | Tovorafenib | low grade glioma | predicted - sensitive | detail... |
FGFR1 K656E | Erdafitinib | low grade glioma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03585465 | Phase Ib/II | Capecitabine + Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Cyclophosphamide + Vinblastine Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Nivolumab | Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors | Recruiting | FRA | BEL | 0 |
NCT04283669 | Phase II | Crizotinib | Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110) | Active, not recruiting | USA | 0 |
NCT04374305 | Phase II | Brigatinib | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) | Recruiting | USA | 0 |
NCT04485559 | Phase I | Everolimus + Trametinib | Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | Recruiting | USA | 0 |
NCT04576117 | Phase III | Selumetinib Selumetinib + Vinblastine | A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma | Recruiting | USA | CAN | 0 |
NCT04773782 | Phase Ib/II | Avapritinib | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | Recruiting | USA | ITA | GBR | FRA | DEU | CAN | AUT | AUS | 1 |
NCT04775485 | Phase II | Tovorafenib | A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1) | Recruiting | USA | GBR | DEU | CAN | AUS | 6 |
NCT04923126 | Phase Ib/II | PD-0325901 | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | Recruiting | USA | 0 |
NCT05076513 | Phase I | Niraparib | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | Recruiting | USA | 0 |
NCT05180825 | Phase II | Vinblastine Trametinib | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy (PLGG - MEKTRIC) | Recruiting | FRA | 0 |
NCT05188508 | Phase II | Olaparib + Pembrolizumab + Temozolomide | Pembrolizumab, Olaparib, and Temozolomide for People With Glioma | Recruiting | USA | 0 |
NCT05222165 | Phase Ib/II | Infigratinib | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations (NEWEL) | Withdrawn | USA | DEU | CAN | 0 |
NCT05303519 | Phase II | DS-1001b | Safusidenib Phase 2 Study in IDH1 Mutant Glioma | Recruiting | USA | 0 |
NCT05345002 | Phase II | Retifanlimab + Tretinoin | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | Recruiting | USA | 0 |
NCT05406700 | Phase I | Niraparib | Niraparib In Recurrent IDH 1/2 Gliomas | Recruiting | USA | 0 |
NCT05566795 | Phase III | Tovorafenib | DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Recruiting | USA | ESP | DEU | CAN | AUS | 11 |
NCT05577416 | Phase I | DS-1001b | A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma (AB-218-IIT-201) | Recruiting | AUS | 0 |
NCT05804227 | Phase I | Ulixertinib | Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults | Recruiting | USA | 0 |